H2O Innovation Sets Sail with The Ocean Race Europe 2025
Article content
Article content
Sailing races like The Ocean Race Europe also create genuine equal opportunity by focusing on what truly matters: skill, endurance, and teamwork. H 2 O Innovation is proud to highlight the participation of Pip Hare, a professional British offshore sailor and the eighth woman in history to finish the Vendée Globe. The presence of this accomplished female skipper further demonstrates leadership opportunities for women in this unique sport. For H 2 O Innovation, the parallels between high-performance sailing teams and successful business teams are striking, as they both require diverse skill sets, collaborative leadership, adaptability under pressure, and the ability to navigate complex, changing environments.
Article content
As the race unfolds across Europe, the Corporation will host a series of exclusive events to celebrate their shared passion for water, innovation and sustainable partnerships.
Article content
Throughout August and September, The Ocean Race will stop in Kiel (Germany), Portsmouth (United Kingdom), Cartagena (Spain), Nice (France), Genova (Italy), and Boka Bay (Montenegro). In many of these ports, H 2 O Innovation will bring together customers, distributors and members of its global team to connect in a meaningful and inspiring setting. These strategic gatherings will enable stakeholders to engage with Canada Ocean Racing team members and gain valuable insights into the dynamic relationship between water resources and high-performance ocean racing.
Article content
More than a sporting event, this journey across Europe reflects H 2 O Innovation's commitment to building strong human connections, fostering collaboration and shaping a more sustainable future for the water sector. 'As we sail from port to port, we look forward to sharing this unique adventure with our global community. We are so proud to stand beside the Be Water Positive sailboat on its journey to making history by raising awareness around water scarcity and championing sustainable water practices worldwide, ' said Frédéric Dugré, President and CEO of H 2 O Innovation. About Canada Ocean Racing – Be Water Positive
Canada Ocean Racing, founded by Scott Shawyer, is a Canadian offshore sailing team competing in the IMOCA Globe Series and striving toward the 2028 Vendée Globe. While navigating across the world's oceans and seas, the team at Canada Ocean Racing witnesses firsthand the impact of what happens on land – plastics in gyres, algal blooms in warming seas, and pollution carried downstream into the ocean. Despite its apparent abundance, clean freshwater is a scarce and invaluable resource. By promoting a message of water positivity, they aim to shed light on global water scarcity and inspire positive change in how we manage our precious water resources and protect our environment. For more information, visit Canada Ocean Racing.
Article content
Article content
2
Article content
O Innovation is a water solutions company focused on providing best-in-class technologies and services to its customers. The Corporation's activities rely on five pillars: (i) Water Technologies & Services (WTS) applies membrane technologies and engineering expertise to deliver equipment and services to municipal and industrial water, wastewater, and water reuse customers, (ii) Specialty Products (SP) is a set of businesses that manufacture and supply a complete line of specialty chemicals, consumables, and engineered products for the global water treatment industry, (iii) Operation & Maintenance (O&M) provides contract operations and associated services for water and wastewater treatment systems; (iv) Water Infrastructure Development (WID) is developing WaterHubs
Article content
.
Article content
Source:
Article content
H
Article content
2
Article content
O Innovation Inc.
Article content
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
16 hours ago
- CTV News
Gainsborough Road closes overnight starting Sunday
A road closure west of London begins at 7:00 p.m. on Sunday. Gainsborough Road will be closed between Hyde Park Road and Rotary Link trail until approximately 6:00 a.m. on Monday. The closure will allow for paving work, according to the City of London. The city urges people to follow all posted signs and find alternative directions.
Globe and Mail
a day ago
- Globe and Mail
Femasys Revenue Jumps 85 Percent in Q2
Key Points Revenue surged 84.8% to $0.41 million (GAAP) in Q2 2025, far outpacing consensus estimates (GAAP) but still early-stage in scale. FemBloc gained its first-ever European approval; FemaSeed and FemVue secured new regulatory clearances and partnerships. Net loss (GAAP) narrowed slightly to $4.59 million, while cash reserves (GAAP) dropped to $3.22 million, bringing a near-term cash crunch. These 10 stocks could mint the next wave of millionaires › Femasys (NASDAQ:FEMY), a women's health medical technology firm developing permanent birth control and fertility solutions, released its second quarter 2025 results on August 8, 2025. The earnings report was marked by strong revenue growth to $0.41 million (GAAP)—an 84.8% jump in GAAP sales from the prior year period—driven by accelerating early-stage sales of FemaSeed intratubal insemination devices and FemVue diagnostic systems. This figure (GAAP revenue of $409,268) came in far above analyst estimates. The company posted a GAAP net loss of $4.59 million, a slight improvement from the $4.68 million GAAP net loss in Q2 2024. Diluted earnings per share (GAAP) was slightly better than analyst estimates at $(0.16). Despite clear commercial and regulatory progress, continued operating losses and a $3.22 million cash balance as of June 30, 2025 mean Femasys will need additional funding within the next quarter to sustain operations. Source: Analyst estimates for the quarter provided by FactSet. Femasys at a Glance and Business Focus Femasys designs and commercializes non-surgical products for women's reproductive health needs. Its main portfolio spans permanent birth control devices—most notably the FemBloc system—and fertility-related solutions like FemaSeed and FemVue. Recent company focus has been on winning new regulatory approvals, especially for FemBloc, and moving early-stage products from research and development into wider commercial sales. Key success factors for Femasys include clearing regulatory hurdles in each market, gaining adoption from clinics and patients, and forming the right distribution partnerships. Protecting its intellectual property is also essential given the specialized nature of its technology. Quarter Highlights: Financial and Product Progress Revenue (GAAP) climbed 84.8%, driven by sales of FemaSeed and FemVue. A roughly $400,000 order from Spain signals a pivotal step in international expansion efforts. Sales of FemaSeed intratubal insemination devices and FemVue diagnostic products—tools that facilitate fertility assessment—drove most of the top-line gain. Together, these products represent the company's early moves beyond the U.S. market. On the regulatory front, Femasys achieved a series of important clearances: FemBloc received its first European approval, marking the first global regulatory sign-off for a non-surgical permanent birth control option in the company's portfolio. FemaSeed and FemVue also gained approvals in Australia and New Zealand, expanding potential markets and laying groundwork for future sales. Ongoing enrollment in U.S. pivotal trials for FemBloc continues, which will be crucial for future coverage and adoption in the American healthcare market. The company expanded its reach through new partnerships. It announced a relationship with the Carolinas Fertility Institute, an eight-clinic network in the U.S, to offer FemaSeed to more patients. Distribution partnerships in Spain will support further commercialization of FemBloc. Femasys also shored up its patent portfolio, receiving notice of intent to grant new patents in Europe and the U.S. for FemBloc and FemaSeed, maintaining its lead in the emerging non-surgical device category. Financially, the net loss (GAAP) narrowed slightly to $4.59 million, reflecting both increased sales and a 28.4% drop in research and development expense as products transition to the commercial phase. However, cash burn remained high: the $3.22 million cash balance at June 30, 2025 gives the company only enough runway to operate into early fourth quarter, without additional funding. The company raised $4.5 million in new equity but continued operating losses have quickly reduced available resources. Inventory increased 71.8% year-to-date (as of June 30, 2025), showing strategic preparation for expected sales but also a concentration of capital in unsold goods. The share count rose from 23,355,926 as of December 31, 2024, to 32,575,407 as of June 30, 2025. Femasys does not currently pay a dividend. Looking Forward Femasys management did not provide specific revenue or earnings targets for the coming quarters or for fiscal 2025. Leadership emphasized that the next stages will focus on translating recent approvals and pilot orders into routine commercial adoption, particularly in the European Union and new Asia-Pacific markets, and continuing to build distribution and clinic partnerships. Given the current cash position as of June 30, 2025, the company expects its cash and cash equivalents will be sufficient to fund operations into the early fourth quarter of 2025. The expanding international footprint and product pipeline, along with progress on intellectual property protection, remain important areas for investors to monitor in the coming periods. FEMY does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,047%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Winnipeg Free Press
a day ago
- Winnipeg Free Press
Maritime provinces, Ottawa announce $9 million to help restore regional air travel
CHARLOTTETOWN – The Maritime provinces and Ottawa are spending $9 million to help restore air travel between Prince Edward Island, New Brunswick and Nova Scotia. Under a three-year pilot program with PAL Airlines, daily flights will be offered between Halifax, Sydney, N.S., Charlottetown, Fredericton and Moncton, N.B. Passengers are expected to fly with the service later this year, although exact dates aren't yet known. The joint funding includes $5 million from the Atlantic Canada Opportunities Agency, $2.9 million from Nova Scotia, $840,000 from P.E.I. and $458,000 from New Brunswick. P.E.I. Premier Rob Lantz and Island MP Sean Casey made the announcement Friday at the Charlottetown airport with Nova Scotia Premier Tim Houston and Gilles LePage, minister responsible for New Brunswick's Regional Development Corporation. Monday Mornings The latest local business news and a lookahead to the coming week. The announcement comes after the Council of Atlantic Premiers formed a working group in February 2023 on regional air travel that included government and airport authority representatives. This report by The Canadian Press was first published Aug. 8, 2025.
